Business Wire

DE-DERMALIQ

14.12.2022 14:27:37 CET | Business Wire | Press release

Share
Dermaliq Therapeutics Announces First Participant Randomized in Phase 1b/2 Trial Evaluating DLQ01 Solution for Treatment of Androgenic Alopecia

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first participant randomized in a Phase 1b/2a trial with DLQ01 solution, a topical Prostaglandin F2α analogue. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with androgenic alopecia (male pattern baldness).

“Topical application of prostaglandin F2α analogue eyedrops has already been demonstrated to grow eyelashes when used to treat glaucoma. These agents could potentially also stimulate hair regrowth in androgenic alopecia in man and woman. However, to date difficulties in topical delivery of this class of compounds into the hair follicle have limited their development,” said Prof. Rod Sinclair, MD, Professor of Dermatology at the University of Melbourne, and Director of Epworth Dermatology.

DLQ01 is designed to overcome the challenges of topical delivery of this drug class with an excellent safety profile. “This trial evaluates how the unique properties of a topical formulation based on hyliQ®, Dermaliq’s novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability, can facilitate targeted delivery of a Prostaglandin F2α analogue into hair follicles,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “We are convinced that Dermaliq’s hyliQ® technology has the potential to transform follicular and dermal delivery of a broad range of active ingredients and that DLQ01 is just the start of a promising pipeline targeting follicular delivery.”

This randomized, blinded, vehicle-controlled Phase 1b/2a trial at Sinclair Dermatology, Melbourne Australia is designed to evaluate the safety and efficacy profile over a 6-month treatment period of two dose strengths of DLQ01 and its vehicle and compared against the market product Rogaine® (Minoxidil) in men diagnosed with androgenic alopecia. A targeted total of 120 patients, 30 per treatment group, will be enrolled. Trial completion is expected in Q4 2023.

“DLQ01 is the third clinical trial in dermatology we initiated in 2022,” said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant achievement towards Dermaliq's goal of developing a new drug category of superior topical prescription therapeutics alongside medical skin care OTC products that address the significant unmet medical need for safe and effective therapies for patients in dermatology.

Delivering clinical proof of concept data with our game-changing, proprietary, hyliQ® technology platform in three different major dermatology indications by 2023 will open the door to new partnerships and support our goal to become a leading, dermatology-focused pharmaceutical company with global reach.”

About DLQ01

DLQ01 solution is a topical prostaglandin (PG) F2α drug, designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness. DLQ01 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQ®” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQ® technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ01. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of December 15, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for androgenetic alopecia, DLQ01, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ01, hyliQ®, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQ® technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ01 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005635/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release

Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta

SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release

Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release

With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release

The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release

Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye